• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Techaging

Bryan Johnson is being used as a human guinea pig in unproven gene therapy injections worth $25,000 a pop in an island off Honduras

Orianna Rosa Royle
By
Orianna Rosa Royle
Orianna Rosa Royle
Associate Editor, Success
Down Arrow Button Icon
Orianna Rosa Royle
By
Orianna Rosa Royle
Orianna Rosa Royle
Associate Editor, Success
Down Arrow Button Icon
December 21, 2023, 7:19 AM ET
Bryan Johnson on stage.
Swapping blood with his 17-year-old son and undergoing daily body scans wasn't enough for the 46-year-old centi-millionaire Bryan Johnson who wants to be 18 again.Kyle Grillot—Bloomberg via Getty Images

With an estimated net worth of around $400 million, tech entrepreneur Bryan Johnson has access to the world’s best health care. But swapping blood with his 17-year-old son and 70-year-old father and undergoing daily body scans by a team of 30 doctors isn’t quite cutting it for the 46-year-old centi-millionaire who wants to be 18 again.

Recommended Video

Now, the Blueprint founder is taking trips to the remote Caribbean island of Roatán to be injected with a genetically enhancing drug that’s not been approved by the FDA—and according to at least one scientist “will kill someone”.

At $25,000 a go, the gene therapy works by turbocharging the body’s production of follistatin—a protein that helps manage the production of other proteins and hormones—to reduce inflammation, increase muscle mass, and improve bone density. It is, according to Minicircle Inc, the small U.S. startup behind the therapy, one of humanity’s best hopes for “extreme longevity”.

The company opted not to charge Johnson for the follistatin therapy—but apparently, their treatment is a bargain.

“Most gene therapies cost more than $1 million a pop,” Walter Patterson, Minicircle’s co-founder and chief scientific officer, told Bloomberg. “This therapy is made so that anyone in the world can have access to it.”

Minicircle has yet to publish clinical trial data for its follistatin therapy, which is the first in a series of products Minicircle plans to roll out. It’s why scientists are issuing stark warnings about the dangers of trying out unregulated gene therapies.

“These have no evidence for working, don’t make sense from a scientific perspective and likely will kill someone by inducing cancer or liver failure,” Christin Glorioso, a physician and neuroscientist, wrote about follistatin and other unregulated gene therapies in her longevity and health newsletter.

A former FDA official helped Johnson weigh up the risks

For Minicircle, the benefit of gaining endorsement from a longevity influencer like Johnson is clear. “He’s by far the most high-profile person to come down here,” Minicircle co-founder Mac Davis told Bloomberg. “Bryan is giving us something worth more than what we would charge him.” 

But why would Johnson forgo FDA approvals to become a human guinea pig for the startup? Certainly, saving money doesn’t come into it.

In reality, the youth-chasing executive and his main doctor, Oliver Zolman, had already created a list of around 20 radical treatments with supposed longevity benefits—and follistatin was one of them.

Their risk-benefit analysis included having their own team of scientists and a former FDA official shower the Minicircle team with questions. Evidently, the answers were good enough for Johnson to give the treatment a go and he received his first dosage on Sept. 10, according to his Instagram. 

“I am now a genetically enhanced human,” Johnson exclaimed, while pointing out the treatment’s benefits in mice. 

“Follistatin gene therapy ranks 7th among lifespan studies, extending mouse lifespan by 30%,” he added.

Indeed, animal studies found that mice who were injected with follistatin had improved age-related loss of muscle and bone density. However, the benefits of follistatin have yet to be studied on healthy human participants.

For its medical trial, Minicircle selected 44 people aged 23 to 89 to be injected with the same dosage of follistatin and then tracked for three months. According to Minicircle—which has yet to publish the trial data—participants managed to shave off around 11 years from their genetic age. 

Johnson on the other hand has been open about how successful—or unsuccessful—various parts of his $2-million-a-year regime have been. Since launching Blueprint in 2021, with the aim of monitoring and reversing his biological age, he’s been published his progress on the company’s website for all to follow along.

Since becoming “genetically enhanced”, he’s reported a 160% spike in his body’s follistatin levels, according to Bloomberg. But he hasn’t yet set new personal records while working out—with the exception of finally being able to rip his shirt off just 14 days after the treatment.

Fortune Brainstorm AI returns to San Francisco Dec. 8–9 to convene the smartest people we know—technologists, entrepreneurs, Fortune Global 500 executives, investors, policymakers, and the brilliant minds in between—to explore and interrogate the most pressing questions about AI at another pivotal moment. Register here.
About the Author
Orianna Rosa Royle
By Orianna Rosa RoyleAssociate Editor, Success
Instagram iconLinkedIn iconTwitter icon

Orianna Rosa Royle is the Success associate editor at Fortune, overseeing careers, leadership, and company culture coverage. She was previously the senior reporter at Management Today, Britain's longest-running publication for CEOs. 

See full bioRight Arrow Button Icon

Latest in Tech

Jay Clayton
LawCrime
25-year DEA veteran charged with helping Mexican drug cartel launder millions of dollars, secure guns and bombs
By Dave Collins, Michael R. Sisak and The Associated PressDecember 6, 2025
4 minutes ago
Elon Musk
LawSocial Media
Elon Musk’s X fined $140 million by EU for breaching digital regulations
By Kelvin Chan and The Associated PressDecember 6, 2025
19 minutes ago
Sarandos
InvestingM&A
Netflix’s $5.8 billion breakup fee for Warner among largest ever
By Elizabeth Fournier and BloombergDecember 6, 2025
42 minutes ago
index
Investingindex funds
Quant who said passive era is ‘worse than Marxism’ doubles down
By Denitsa Tsekova, Vildana Hajric and BloombergDecember 6, 2025
2 hours ago
meta
LawSocial Media
‘Its own research shows they encourage addiction’: Highest court in Mass. hears case about Instagram, Facebook effect on kids
By Michael Casey and The Associated PressDecember 6, 2025
3 hours ago
Amit Walia
CommentaryM&A
Why the timing was right for Salesforce’s $8 billion acquisition of Informatica — and for the opportunities ahead
By Amit WaliaDecember 6, 2025
3 hours ago

Most Popular

placeholder alt text
Economy
Two months into the new fiscal year and the U.S. government is already spending more than $10 billion a week servicing national debt
By Eleanor PringleDecember 4, 2025
2 days ago
placeholder alt text
Success
‘Godfather of AI’ says Bill Gates and Elon Musk are right about the future of work—but he predicts mass unemployment is on its way
By Preston ForeDecember 4, 2025
2 days ago
placeholder alt text
Success
Nvidia CEO Jensen Huang admits he works 7 days a week, including holidays, in a constant 'state of anxiety' out of fear of going bankrupt
By Jessica CoacciDecember 4, 2025
2 days ago
placeholder alt text
Success
Nearly 4 million new manufacturing jobs are coming to America as boomers retire—but it's the one trade job Gen Z doesn't want
By Emma BurleighDecember 4, 2025
2 days ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
23 hours ago
placeholder alt text
Real Estate
‘There is no Mamdani effect’: Manhattan luxury home sales surge after mayoral election, undercutting predictions of doom and escape to Florida
By Sasha RogelbergDecember 4, 2025
2 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.